Dopamine agonist effects on hyperglycemia and the cardiometabolic profile
Abstract
Dopamine plays a complex role in modulation of cardiometabolic parameters. Positive effects on glucose control and parameters of the metabolic syndrome have been demonstrated in both pre-clinical and clinical data. Pharmacologically, bromocriptine- quick release, a dopamine agonist used for treatment in type 2 diabetes mellitus, provides modest improvement in hemoglobin A1c (HbA1c), weight and lipids. Additionally, bromocriptine has a beneficial overall cardiovascular risk profile. The anti-hyperglycemic effects of bromocriptine are thought to be mediated through the circadian rhythm, but interesting research suggests that central dopamine action may underlie the beneficial cardiometabolic effects. This review will examine the pre-clinical and clinical data regarding known metabolic changes observed with dopamine agonist therapy. The role of prolactin, as a mediator of cardiometabolic risk or a signal of dopamine action, will be discussed.
Keywords
Full Text:
Subscribers OnlyReferences
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011;63(1):182-217.
Young RA. Fat, energy, and mammalian survival. Am Zool 1976;16(4):699-710.
Meier AH, Cincotta AH. Circadian rhythms regulate the expression of the thrift genotype/phenotype. Diabetes Rev 1996;4:464-87.
Cincotta AH, Schiller BC, Landry RJ, Herbert SJ, Miers WR, Meier AH. Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat. Chronobiol Int 1993;10(4):244-58.
Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother 2010;44(11):1775-85.
Pantheon Inc., Cycloset (Package Insert) [Internet], Pantheon Inc., Cincinnati, Ohio, 2009, Available from: http://www.accessdata.fda.gov/drugsatfda docs/label/2009/ 020866lbl.pdf (accessed 28 July 2016).
Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006;17(3):110–6.
Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997;61(10):951-6.
Liang Y, Lubkin M, Sheng H, Scislowski PW, Cincotta AH. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta 1998;1405(1-3):1-13.
Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000;71(1):68-78.
Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta AH. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord 1999;23(4):425-31.
Jetton TL, Liang Y, Cincotta AH. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. Metabolism 2001;50(11):1377-84.
Nade VS, Kawale LA, Todmal UB, Tajanpure AB. Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats. Indian J Pharmacol 2012;44(6):688-93.
Liang Y, Jetton TL, Lubkin M, Meier AH, Cincotta AH. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998;54(7):703-11.
Durant S, Coulaud J, Homo-Delarche F. Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev Diabet Stud 2007;4(3):185-94.
Kumar VSH, MBV, ANP, Aithal S, Baleed SR, Patil UN. Bromocriptine, a dopamine (D2) receptor agonist, used alone and in combination in sub-therapeutic doses to ameliorate hyperglycaemia. J Clin Diagn Res 2013;7(9):1904-7.
Holstad M, Sandler S. Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice. J Endocrinol 1999;163(2):229-34.
Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12(2):153–75.
Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34(4):789–94.
Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc 2012;1(5):e002279.
Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23(8):1154-61.
Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004; 62(2):55–9.
Liang W, Gao L, Li N, Wang B, Wang L, Wang Y, Yang H, You L, Hou J, Chen S, Zhu H, Jiang Y, Pan H. Efficacy and safety of bromocriptine-QR in type 2 diabetes: a systematic review and meta-analysis. Horm Metab Res 2015;47(11):805-12.
Gaziano JM, Cincotta AH, O’Connor CM, Ezrokhi M, Rutty D, Ma ZJ, Scranton RE. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33(7):1503–8.
Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, Murthy M, Ghanghas RG. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocrinol Metab 2011;15(Suppl 1):S33-9.
Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid prole in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8(10):1683-1707.
Florez H, Scranton R, Farwell WR, Defronzo RA, Ezrokhi M, Gaziano JM, Cincotta AH. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab 2011;2(7):142.
Taghavi SM, Fatemi SS, Rokni H. Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med. J Malaysia 2012; 67(4): 390-2.
Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992;48(3):248-53.
Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19(6):667-70.
Chamarthi B, Gaziano JM, Blonde L, Vinik A, Scranton RE, Ezrokhi M, Rutty D, Cincotta AH. Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res 2015;2015:157698.
Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, Chen YD. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997;20(11):1697-701.
Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry 2009;70(5):765–6.
Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119(1):4–14.
Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L’Italien G. The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18(9):791–9.
Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011;14(3):199–207.
Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147(1):77–84.
Krysiak R, Okopien B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol 2015;116(3):251-6.
Krysiak R, Okrzesik J, Okopien B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2015;49(1):242-9.
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006;64(4):366–70.
Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract 2014;20(5):447–51.
Haring R, Friedrich N, Volzke H, Vasan RS, Felix SB, Dorr M, Meyer zu Schwabedissen HE, Nauck M, Wallaschofski H. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J 2014;35(18):1215–21.
DOI: http://dx.doi.org/10.18103/imr.v2i7.153
Refbacks
- There are currently no refbacks.